Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg/week, tirzepatide 15 mg/week) produce significant weight loss (10–21%) and metabolic improvements in adults with obesity, though outcomes are limited by gastrointestinal side effects and long-term adherence challenges.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (10-21%) and improving metabolic health. They work by slowing digestion and reducing appetite. Expect gastrointestinal side effects like nausea, which often improve over time. These drugs require ongoing use and can be expensive, so discuss insurance coverage and side effect management with your doctor.
GLP - 1 receptor agonists (e.g. semaglutide, liraglutide) were originally developed for glycemic control in type 2 diabetes. Subsequent clinical trials revealed their significant potential for reducing weight in non - diabetic patients. Their benefits are for example slower gastric emptying, enhanced satiety signals, and appetite suppression... These medications also improved blood sugar control and lipid levels.
Why this rating
Based on multiple meta-analyses and RCTs cited in the review.
Source
INNOVATIONS IN OBESITY TREATMENT – GLP – 1 PHARMACOTHERAPY AND BARIATRIC SURGERY
Piotr Bartnik et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.3(47).2025.3682
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →